Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Christine H ChungJiannong LiConor E SteuerPriyanka BhatejaMatthew JohnsonJude MasannatMaria I PooleFeifei SongJuan C Hernandez-PreraHelen MolinaBruce M WenigSunil KumarCharlotte KuperwasserPhilip J StephensJoaquim M FarinhasDong M ShinJulie A KishJameel MuzaffarKedar S Kirtane James W RoccoMichael J SchellNabil F SabaMarcelo Bonomi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The combination of cetuximab and nivolumab is effective in patients with both previously treated and untreated R/M HNSCC and warrants further evaluation.

Keyphrases

phase ii
clinical trial
locally advanced
open label
squamous cell carcinoma
metastatic colorectal cancer
rectal cancer
wild type
double blind
small cell lung cancer
phase iii
placebo controlled
radiation therapy
study protocol
randomized controlled trial